FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL			
OMB Number:	3235-0287		
Estimated average burden			
hours per response:	0.5		

	Check this box if no longer subject to Section 16. Form 4
1 1	or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

						or Section	n 30(h) of the	Investment Co	mpany Act o	f 1940					
Name and Address of Reporting Person*     Grossman William					2. Issuer Name and Ticker or Trading Symbol BELLICUM PHARMACEUTICALS, INC [ BLCM ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director			er
											X	Officer (give title	below)	Other (sp	ecify below)
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year)							Sr. VP, Chief Medical Officer			
C/O BELLICUM PHARMACEUTICALS, INC.					02/01/2019										
2130 W. HOLCOMBE BLVD., STE. 800															
(Street)					4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)				
HOUSTON T	IOUSTON TX 77030									X					
										Form filed by More than One Reporting Person					
(City) (S	tate)	(Ziţ	))												
			T	able I - I	Non-Der	ivative Sec	curities Ac	quired, Dis	sposed of	f, or Beneficially Owi	ned				
1. Title of Security (Instr. 3)				2. Transact Date	Execu	Execution Date,	3. Transaction 4. Securities Acquired ( Code (Instr. 8) 3, 4 and 5)		ities Acquired (A) or Dispose 5)	```   в	Amount of Securiti eneficially Owned F	ollowing Dir		7. Nature of Indirect Beneficial	
					(Month/Day	//Year) if any (Month/Day/Year)	h/Day/Year)	Code V	Amount	(A) or (D)		eported Transaction nstr. 3 and 4)	ı(s) (In	str. 4)	Ownership (Instr. 4)
				Table I						or Beneficially Owne e securities)	d		·		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	nversion Date Exercise (Month/Day/Year) ice of rivative	Execution Date, if any (Month/Day/Year)	4. Transac (Instr. 8)	tion Code	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlyin Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following	of 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share	Re	Reported Transaction (Instr. 4)	(s)	
Stock Option (right to buy)	\$3.35	02/01/2019		Α		82,500		(1)	01/31/2029	Common Stock	82,500	\$0	82,500	D	
Evalenation of Decreases.	,					•	•	,		,		_			

1. 25% of the shares subject to the stock option vest and become exercisable on January 1, 2020, and the remaining shares subject to the stock option vest and become exercisable in 36 equal monthly installments thereafter.

## Remarks:

EXHIBIT LIST: EX-24 Power of Attorney

/s/ Rosemary Y. Williams, Attorney-in-Fact 02/05/2019
\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see instruction 4 (b)(v).

\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

### POWER OF ATTORNEY

Know all, by these presents, that the undersigned hereby constitutes and appoints each of Richard A. Fair, Rosemary Y. Williams and Shane M. Ward, signing inc (1) execute for and on behalf of the undersigned, an officer, director or holder of 10% of more of a registered class of securities of Bellicum Pharmaceuticals

- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute such Form 3, 4 or 5, complete and execute such Ex
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the l The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necess.

  This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with 1

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 8th day of August, 2018.

/s/ William Grossman, M.D. Ph.D (Signature) William Grossman, M.D. Ph.D (Print Name)

181526777 v1